300.51USDMkt Cap: 40.12B USDP/E: 75.70Last update: 2026-05-21
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for h…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap40.12B USD
Enterprise Value40.08B USD
Revenue (TTM)4.29B USD
Gross Profit3.03B USD
Net Income (TTM)313.75M USD
Revenue/Share32.52 USD
Last Price300.51 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees2.5K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS02043Q1076
Valuation
P/E (Trailing)75.70
P/E (Forward)21.51
PEG0.50
EV/EBITDA49.67
EV/Revenue9.35
P/S9.36
P/B37.29
EPS (TTM)3.97
EPS (Forward)13.97
52W Range
293.0090% of range301.30
52W High301.30 USD
52W Low293.00 USD
Profitability
Gross Margin81.64%
Oper. Margin23.02%
EBITDA Margin18.82%
Profit Margin8.45%
ROE39.76%
ROA6.32%
Growth
Revenue Growth96.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF524.08M USD
CapEx (TTM)58.70M USD
FCF Margin4.78%
FCF Yield0.51%
Net Debt-38.99M USD
Net Debt/EBITDA-0.05
Balance Sheet
Debt/Equity1.62
Current Ratio3.13
Quick Ratio2.88
Book Value/Sh8.059 USD
Cash/Share22.54 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.8 (Buy)
Target (Mean)445.81 USD
Target Range310.00 USD – 566.00 USD
# Analysts27
Ownership
Shares Out.133.51M
Float132.96M
Insiders0.18%
Institutions102.16%
Short Interest
Short Ratio4.3d
Short % Float4.77%
Short % Out.3.58%
Shares Short4.77M
Short (prev mo.)5.06M
Technical
SMA 50310.71 (-3.3%)
SMA 200389.00 (-22.7%)
Beta0.30
S&P 52W Chg28.31%
Avg Vol (30d)578.59K
Avg Vol (10d)914.81K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—